Cost per QALY gained with one year treatment (€)
| No | Incremental cost (€)* | QALY gain* | Cost/QALY (€) | |
|---|---|---|---|---|
| 1€ = 9.05 SEK. | ||||
| *Incremental costs and QALY gains are calculated compared with baseline, assuming that without TNF inhibitor treatment patients would remain at the baseline level throughout the year; †base case assumption for QALY gain: improvement of utility after three months. | ||||
| Direct costs only | 116 | 12455 | 0.28 | 44500 |
| Base case† | 116 | 12184 | 0.28 | 43500 |
| Improvement linear | 116 | 12184 | 0.19 | 64100 |
| Improvement after 6 weeks | 116 | 12184 | 0.33 | 36900 |
| Drop outs included | 160 | 10727 | 0.2 | 53600 |
| Patients with HAQ <0.6 at baseline | 8 | 14131 | 0.11† | 128500 |
| Patients with HAQ 0.6<1.1 at baseline | 21 | 11131 | 0.18† | 61800 |
| Patients with HAQ 1.1<1.6 at baseline | 30 | 15241 | 0.25† | 61000 |
| Patients with HAQ 1.6<2.1 at baseline | 36 | 11176 | 0.30† | 37300 |
| Patients with HAQ ⩾2.1 at baseline | 21 | 6888 | 0.16† | 43000 |